Pyrimidine EGFR Inhibitors for Exon 20 Insertion Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for lung cancer, particularly those targeting EGFR mutations, fail to provide clinical benefit for many patients, and there is a lack of effective treatments for oncogenic drivers like insertions in the exon 20 gene of EGFR.
Innovation Solution
Development of pyrimidine compounds that act as selective inhibitors of EGFR, including specific mutations and drug-resistant forms, to treat cancers and inflammatory diseases associated with EGFR family kinase mutants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If currently available therapies targeting EGFR mutations are used, then treatment is provided for common EGFR mutations, but clinical benefit is not achieved for many patients with other EGFR mutations including exon 20 insertions
Solution Approach 1:
The pyrimidine compound is designed to inhibit multiple EGFR mutation types including exon 19 deletions, exon 21 substitutions, and exon 20 insertions through a single agent, making the therapy universally effective across diverse EGFR-mutant NSCLC cases rather than requiring mutation-specific treatments
2Adaptability or versatility
If three generations of tyrosine kinase inhibitors are developed for common EGFR mutations, then treatment options are expanded for specific mutations, but therapies are not available for other oncogenic drivers including exon 20 insertions
Solution Approach 1:
The compound serves as a multi-functional inhibitor capable of targeting multiple EGFR mutation types simultaneously, providing broad treatment coverage while maintaining reliable therapeutic effectiveness across different mutation contexts
Solution Approach 2:
The pyrimidine compound structure is optimized with specific parameter changes including the R1 substituent options (cyclopropyl, fluorine, chlorine, methyl) and R2 substituent variations to achieve appropriate binding affinity and selectivity parameters for multiple EGFR mutation types while maintaining drug-resistant form inhibition
3Reliability
If pyrimidine compounds are developed as selective EGFR inhibitors, then effectiveness against EGFR mutants is improved, but safety profiles and toxicity must be optimized
Solution Approach 1:
The compound exhibits local quality through selective inhibition of EGFR mutants while sparing wild-type EGFR and other kinases, achieving high inhibition effectiveness for mutant forms while maintaining an acceptable safety profile through mutation-specific targeting
Solution Approach 2:
The therapeutic index is optimized through parameter changes in the molecular structure, particularly the R1 and R2 substituent selections that fine-tune binding affinity for mutant EGFR versus wild-type, thereby improving inhibition effectiveness while controlling toxicity through selective action
Data Source
AI summary
The present disclosure relates to a class of pyrimidine compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, stereoisomers, solvates, and hydrates thereof. The present disclosure also relates to a process of preparation of these pyrimidine compounds, pharmaceutical compositions containing them, and medicinal applications thereof.